Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women
NCT ID: NCT00418249
Last Updated: 2007-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
40 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.
NCT05599243
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
NCT01189279
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
NCT03495817
Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia
NCT05611593
Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
NCT01325350
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AS101
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinically diagnosed for AGA, according to Ludwig scale I-II.
Exclusion Criteria
* Use of Minoxidil within 3 months prior to entering study.
* Women who have underwent hair transplantation.
* Use of drugs with androgenic or anti-androgenic effects.
* Any other type of hair loss.
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rabin Medical Center
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Danny Ben-Amitai, M.D.
Role: PRINCIPAL_INVESTIGATOR
Rabin Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Danny Ben Amitai, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Danny Ben Amitai
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
#69 REV 00
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.